Close

Arbutus Biopharma (ABUS) Says LNP Licensee Alnylam (ANLY) Receives Accelerated Assessment of Patisiran from EMA

November 13, 2017 5:41 PM EST Send to a Friend
Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the Company's lipid ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login